Madrigal Pharmaceuticals Inc
NASDAQ:MDGL

Watchlist Manager
Madrigal Pharmaceuticals Inc Logo
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Watchlist
Price: 267.56 USD -2.12% Market Closed
Market Cap: 5.9B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
N/A
Revenue
Forecast
+23%
Operating Income
Forecast
+24%
Net Income
Forecast
+20%

Wall Street
Price Targets

MDGL Price Targets Summary
Madrigal Pharmaceuticals Inc

Wall Street analysts forecast MDGL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MDGL is 430.37 USD with a low forecast of 250.48 USD and a high forecast of 567 USD.

MDGL Lowest Forecast
Wall Street Target
250.48 USD
6% Downside
MDGL Average Forecast
Wall Street Target
430.37 USD
61% Upside
MDGL Highest Forecast
Wall Street Target
567 USD
112% Upside
Lowest
Price Target
250.48 USD
6% Downside
Average
Price Target
430.37 USD
61% Upside
Highest
Price Target
567 USD
112% Upside
Madrigal Pharmaceuticals Inc Competitors:
Price Targets
LXRX
Lexicon Pharmaceuticals Inc
302% Upside
300122
Chongqing Zhifei Biological Products Co Ltd
56% Upside
TGTX
TG Therapeutics Inc
25% Upside
AZT
Arcticzymes Technologies ASA
20% Upside
LXRX
Lexicon Pharmaceuticals Inc
302% Upside
300122
Chongqing Zhifei Biological Products Co Ltd
56% Upside
TGTX
TG Therapeutics Inc
25% Upside
AZT
Arcticzymes Technologies ASA
20% Upside
B
377740
BioNote Inc
19% Upside
SBTX
SkinBioTherapeutics PLC
205% Upside
ATYR
aTyr Pharma Inc
408% Upside
B
BCAX
Bicara Therapeutics Inc
265% Upside

Revenue
Forecast

Revenue Estimate
Madrigal Pharmaceuticals Inc

The compound annual growth rate of Madrigal Pharmaceuticals Inc's revenue for the next 3 years is 118%.

N/A
Past Growth
118%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Madrigal Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Madrigal Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-32%
Average Miss
What are analyst estimates?

See Also

Summary
MDGL intrinsic value, competitors valuation, and company profile.
DCF Valuation
MDGL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MDGL stock valuation using valuation multiples.
Wall Street Estimates
MDGL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MDGL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MDGL's stock price target?
Price Target
430.37 USD

According to Wall Street analysts, the average 1-year price target for MDGL is 430.37 USD with a low forecast of 250.48 USD and a high forecast of 567 USD.

What is Madrigal Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
118%

The compound annual growth rate of Madrigal Pharmaceuticals Inc's revenue for the next 3 years is 118%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 256,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.